Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn’s Disease

• Main Authors: Matthias Kelm, Friedrich Anger, Robin Eichlinger, Markus Brand, Mia Kim, Joachim Reibetanz, Katica Krajinovic, Christoph-Thomas Germer, Nicolas Schlegel, Sven Flemming
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: Journal of Clinical Medicine
• Subjects: Crohn’s Disease; surgical therapy; ileocecal resection
• Online Access: https://www.mdpi.com/2077-0383/10/4/731

Despite the increasing incidence and prevalence of Crohn’s Disease (CD), no curative options exist and treatment remains complex. While therapy has mainly focused on medical approaches in the past, growing evidence reveals that in cases of limited inflammation, surgery can suffice as an alternative primary treatment. We retrospectively assessed the disease course and outcomes of 103 patients with terminal Ileitis who underwent primary surgery (<i>n</i> = 29) or received primary medical treatment followed by surgery (<i>n</i> = 74). Primary endpoint was the need for immunosuppressive medication after surgical treatment (ileocecal resection, ICR) during a two-years follow-up. Rates for laparoscopic ICR were enhanced in case of early surgery, but no differences were seen for postoperative complications. In case of immunosuppressive medication, patients with ICR at an early state of disease needed significantly less anti-inflammatory medication during the two-year postoperative follow-up compared to patients who were primarily treated medically. Furthermore, in a subgroup analysis for patients with localized ileocecal disease manifestation, early surgery consistently resulted in a decreased amount of medical therapy postoperatively. In conclusion primary ICR is safe and effective in patients with limited CD, and the need for immunosuppressive medication during the postoperative follow-up is low compared to patients receiving surgery at a later stage of disease.